散发性甲状腺髓样癌中的体细胞RET插入缺失:患病率及对塞尔帕替尼的反应
研究分析287例甲状腺髓样癌(MTC)组织的RET插入缺失(indel)患病率,并描述塞尔帕替尼对携带RET indel的晚期MTC患者的疗效。178例RET阳性中31例(17.4%)为RET框内indel,9种为既往未报道且经MutationTaster判定为致病性。携带indel者呈侵袭性疾病,2例接受塞尔帕替尼治疗获得部分缓解,作者认为这些indel是可操作的突变,推荐分析全基因以避免遗漏。
要点
- 287例MTC组织中178例RET阳性,其中31例(17.4%)携带RET框内indel,147例(82.6%)携带单核苷酸变异(SNV)。
- 9种indel为既往未报道,经MutationTaster判定为致病性。
- 2例RET indel阳性晚期MTC患者接受塞尔帕替尼治疗获得部分缓解。
核心结论
- RET indel在MTC中并不少见,且与侵袭性疾病相关。
- 2例RET indel阳性患者对高选择性RET抑制剂塞尔帕替尼获得部分缓解,作者认为这些RET indel可被视为可操作的突变。
- 为避免遗漏这些变异,作者推荐分析全基因。
研究设计与样本
- 对287例患者的MTC组织采用Ion S5靶向测序进行分析。
- 通过MutationTaster评估所报道indel的功能作用。
- 收集并分析携带RET indel的MTC患者的临床和病理数据。
- 2例携带RET indel的患者接受塞尔帕替尼治疗。
主要发现
- 178例RET阳性病例中,147例(82.6%)携带SNV,31例(17.4%)携带RET框内indel。
- 9种indel为既往未报道,经MutationTaster判定为致病性。
- 携带indel的患者呈侵袭性疾病。
- 2例携带RET indel的患者接受塞尔帕替尼治疗,获得良好反应(部分缓解)。
临床怎么用
- 作者认为RET indel可被视为可操作的突变。
- 为避免遗漏这些变异,作者推荐分析全基因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Although the majority of RET alterations are single nucleotide variants (SNV), small deletions and/or insertions have been reported at variable prevalence. No information about the efficacy of RET-specific inhibitors in patients harboring RET indels has been provided. OBJECTIVE: We present an update on the prevalence of RET indels in medullary thyroid cancer (MTC) and describe the efficacy of selpercatinib in patients with advanced MTC with RET indels. METHODS: The MTC tissues of 287 patients were analyzed using an Ion S5 targeted sequencing. The functional role of the reported indels have been evaluated by MutationTaster. Clinical and pathological data of MTC patients harboring a RET indel were collected and analyzed. Two patients with a RET indel were treated with selpercatinib. RESULTS: Among 178 RET-positive cases, 147 (82.6%) harbored a SNV and 31 (17.4%) a RET in-frame indel. Nine indels were not previously reported and were found to be disease causing by MutationTaster. Patients harboring an indel were found to have an aggressive disease and 2 of them were treated with selpercatinib, experiencing a good response to the treatment. CONCLUSION: These data show that RET indels are not infrequent and correlate with an aggressive disease. Two RET indel-positive patients showed a partial response to the treatment with a highly selective RET inhibitor; thus, these RET indels can be considered actionable mutations. In order to not miss these alterations, the analysis of the full gene is recommended.
引用
- Elisei R, Ciampi R, Matrone A, et al. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. J Clin Endocrinol Metab. 2022. PMID: 35616103. doi:10.1210/clinem/dgac325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。